Reunion Neuroscience raised a $133 million Series A less than two years ago, and it has now replaced its founding CEO with an operator whose entire career has orbited the same bet the company is making: that psychedelic-derived molecules can be engineered into credible psychiatric drugs. That is not a routine leadership swap. It is a signal that Reunion’s board, anchored by MPM BioImpact and Novo Holdings, believes the asset is ready for a different kind of stewardship.
Sahil Kirpekar arrives with a résumé that reads like a deliberate preparation for this specific role. He built deal flow at Atai Life Sciences during the period it acquired Beckley Psytech, then spent more than eight years at Otsuka as Global Head of Business Development executing transactions across CNS and beyond. Across his career he has been responsible for deals totaling several billion dollars in aggregate. That biography matters here because luvesilocin’s RECONNECT Phase 2 data in postpartum depression, presented in January 2026, were strong enough to earn an FDA Breakthrough Therapy Designation in February. A company sitting on a breakthrough-designated asset with Phase 2 trials already underway in adjustment disorder and generalized anxiety disorder needs someone who knows how to run a partnership process and extract full value from that designation, not just manage a clinical organization.
The postpartum depression context is worth understanding precisely. Brexanolone, the first FDA-approved drug specifically for PPD, was later withdrawn from the market after its manufacturer ceased commercializing it, leaving the approved landscape thinner than the science would suggest it should be. Zuranolone exists as an oral option, but PPD treatment remains a category where a well-differentiated single-administration profile could command real clinical attention and real payer interest. Luvesilocin’s “clinically relevant duration of effect” is the claim Kirpekar will need to translate into payer and prescriber language before Phase 3 even starts.
The clearest thing to watch now is whether Kirpekar uses his Atai and Otsuka relationships to pursue a partnership or co-development structure around luvesilocin before a Phase 3 spend forces another financing. Reunion’s $133 million Series A buys time, but a large-pharma CNS deal would reframe this entirely. That transaction, if it comes, is the outcome this appointment is designed to produce.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
